Clinical trials: Cyclooxygenase 2 Inhibitors
Ankylosing Spondylitis
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs candidates a biological therapy that could adequately respond to treatment with etoricoxib This study confirm the result of a previous study in…
- Trial name
- NCT01091675
- Testing
- Etoricoxib
- Where
- 14 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Spanish Foundation of Rheumatology
Uterine Cancer
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
Expression of COX-II has been identified in many types of human cancers. Uterine cancer is the most common gynecologic cancer in the US and there has been an increase in uterine cancer deaths over the past decade mainly due to…
- Trial name
- NCT00231829
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mark H. Einstein
Treatment Resistant Depression, Major Depressive Disorder
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression
The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine
- Trial name
- NCT05615948
- Testing
- VTS-K
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Theresa Jacob, PhD, MPH
Major Depression
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression.
- Trial name
- NCT00510822
- Testing
- Cimicoxib
- Where
- 25 sites in Austria, Czechia and 1 more
- Volunteers
- 169 people
- Sponsor
- Affectis Pharmaceuticals AG
Nasopharyngeal Carcinoma
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.
- Trial name
- NCT02537925
- Testing
- Celecoxib, Nedaplatin, Concurrent Radiotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changjie Huang
Arthritis, Bleeding Ulcer
Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib
The purpose of this study is to compare the effect of Esomeparzole with Placebo in the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor
- Trial name
- NCT00365313
- Testing
- celecoxib, esomeprazole
- Where
- China
- Volunteers
- 273 people
- Sponsor
- Chinese University of Hong Kong
Headache
An End to the Yom Kippur (and Ramadan) Headache
Fasting is a known trigger for headache. People who fast to comply with religious edict have been shown to be prone to headache which becomes more likely to occur with increasing length of fasting, and in people prone to…
- Trial name
- NCT00263094
- Testing
- Rofecoxib
- Where
- Israel
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Spinal Stenosis Lumbar
Clinical Trial of Pregabalin and COX2 in Spinal Stenosis
Aim of this prospective, single-blind, randomized study was to compare the efficacy of the combination of celecoxib and pregabalin and celecoxib only monotherapy for treatment of chronic low-back pain.
- Trial name
- NCT03584074
- Testing
- Pregabalin 75mg, Celebrex 200Mg Capsule
- Volunteers
- 60 people
- Sponsor
- Seoul National University Bundang Hospital
Pancreatic Neoplasms
Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery
In Israel, of the ~1000 patients diagnosed annually with pancreatic cancer (PC), approximately 250 (25 percent) will be eligible for curative surgery, of which 80 percent will succumb to post-surgical metastatic disease.
- Trial name
- BC-PC (NCT03838029)
- Testing
- Propranolol and etodolac
- Where
- 3 sites in Israel
- Volunteers
- 210 people
- Sponsor
- Assaf-Harofeh Medical Center
Rupture; Graafian Follicle
Study of a COX-2 Inhibitor for Prevention of Ovulation
In this study the investigators propose to evaluate a COX-2 inhibitor(meloxicam) to assess its effect on follicular development and find out if this regimen delays or blocks ovulation while maintaining ovarian cyclicity.
- Trial name
- NCT01346137
- Testing
- Meloxicam
- Where
- Chile
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Instituto Chileno de Medicina Reproductiva
Breast Cancer
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing breast cancer in at-risk women.
- Trial name
- NCT00056082
- Testing
- celecoxib
- Where
- 3 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Pain
Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction
This study will evaluate the ability of a new non-steroidal anti-inflammatory drug (NSAID) called rofecoxib to prevent pain following third molar (wisdom tooth) extraction.
- Trial name
- NCT00026819
- Testing
- Rofecoxib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer.
- Conditions
- Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer
- Trial name
- NCT00081263
- Testing
- Celecoxib, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 130 people
- Sponsor
- Gynecologic Oncology Group
Lung Cancer
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00653250
- Testing
- celecoxib, biopsy, therapeutic conventional surgery
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Injection Site Irritation
Effects of Cyclooxygenase (COX) 1-2 Inhibitors on Prevention of Rocuronium Injection Pain
Purpose : The aim of the study is to investigate the effects of cox inhibitors as a rescue agent against the rocuronium pain Methodology : Sixty patients enrolled for the general anesthesia enrolled in this study.
- Trial name
- NCT04582032
- Testing
- Dexketoprofen (KETAVEL 50 mg/2 ml), Saline (Isotonic Saline Solution 0.9% )
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
- Trial name
- NCT00291694
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1).
- Trial name
- NCT07150949
- Testing
- Long-course radiotherapy, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Non Small Cell Lung Carcinoma
Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC
The purpose of this study is to investigate the effect of the adminstration of celecoxib, a cox2-inhibitor in patients with stage II-III non small cell lung cancer receiving radical radiotherapy.
- Trial name
- NCT00181532
- Testing
- Celecoxib
- Where
- Netherlands
- Volunteers
- 102 people
- Sponsor
- Maastricht Radiation Oncology
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Aortic Valve Disease, Myocardial Infarction
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
At present, a variety of antithrombotic regimens are prescribed in the early postprocedure period after transcatheter aortic valve implantation (TAVI).
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke, Bleeding
- Trial name
- POPular-TAVI (NCT02247128)
- Testing
- Aspirin + clopidogrel, Aspirin monotherapy, OAC + clopicogrel
- Where
- 17 sites in Belgium, Czechia and 2 more
- Volunteers
- 1,016 people
- Sponsor
- St. Antonius Hospital